GoAI
Get started
Hinge Health, Inc. logo

Hinge Health, Inc.

HNGE

NYSEHealthcareMedical - Healthcare Information Services

Open in GoAI

Previous close

$88.42

+$2.80 · +3.27%

Aug 21, 4:00 PM ET

HNGE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

62

Undervalued

Momentum

63

Gaining

Sentiment

45

Mixed

Risk resilience

65

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health. Their advanced platform is designed to comprehensively manage a spectrum of needs, including general musculoskeletal care, acute injuries, persistent chronic pain, and post-operative rehabilitation. Furthermore, the company provides essential administrative and operational assistance.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Daniel A. Perez
Listed since
May 22, 2025
Employees
1,437

Market position

Day range

Current $88.42

52-week range

Current $88.42

Open
$85.70
Previous close
$85.62
Volume
1.31M
0.73× average
Average volume
1.78M
Average daily volume
Market cap
6.84B USD
Beta
1.29
Market reference 1
50-day average
$80.9688
+9.20% above average
200-day average
$54.4585
+62.36% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.48B USD
P/E (TTM)
65.66×
P/B (TTM)
20.23×
P/S (TTM)
9.5×
EV / EBITDA
-6.49×
Earnings yield
-14.36%
Free cash flow yield
4.64%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
84.52%
Operating margin
13.01%
Net margin
15.15%
Return on equity
-139.55%
Return on assets
-70.93%
Return on invested capital
-141.34%

Financial health

Debt / equity
0.02×
Current ratio
1.47×
Altman Z-score
8.35
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends97%28%-41%-110%Gross margin, FY2023: 66.33%Gross margin, FY2024: 77.00%Gross margin, FY2025: 79.83%Operating margin, FY2023: -44.59%Operating margin, FY2024: -8.17%Operating margin, FY2025: -92.94%Net margin, FY2023: -36.94%Net margin, FY2024: -3.06%Net margin, FY2025: -89.86%FY2023FY2024FY2025
Gross margin FY2023 66.33%. Gross margin FY2024 77.00%. Gross margin FY2025 79.83%. Operating margin FY2023 -44.59%. Operating margin FY2024 -8.17%. Operating margin FY2025 -92.94%. Net margin FY2023 -36.94%. Net margin FY2024 -3.06%. Net margin FY2025 -89.86%.

Income trends

Revenue

587.86M USD+50.58%

Operating income

−546.37M USD-1612.23%

Net income

−528.26M USD-4326.89%
Income trends across reported periods701.28M USD247.59M USD−206.1M USD−659.79M USDRevenue, FY2023: 292.73M USDRevenue, FY2024: 390.4M USDRevenue, FY2025: 587.86M USDOperating income, FY2023: −130.51M USDOperating income, FY2024: −31.91M USDOperating income, FY2025: −546.37M USDNet income, FY2023: −108.14M USDNet income, FY2024: −11.93M USDNet income, FY2025: −528.26M USDFY2023FY2024FY2025
Revenue FY2023 292.73M USD. Revenue FY2024 390.4M USD. Revenue FY2025 587.86M USD. Operating income FY2023 −130.51M USD. Operating income FY2024 −31.91M USD. Operating income FY2025 −546.37M USD. Net income FY2023 −108.14M USD. Net income FY2024 −11.93M USD. Net income FY2025 −528.26M USD.
Metric (USD)FY2025FY2024FY2023
Revenue587.86M USD390.4M USD292.73M USD
Cost of goods sold118.56M USD89.81M USD98.55M USD
Gross profit469.3M USD300.59M USD194.18M USD
Research and development368.14M USD100.84M USD110.06M USD
Selling, general, and administrative639.41M USD227.54M USD214.64M USD
Operating expenses1.02B USD332.5M USD324.69M USD
Depreciation and amortization5.13M USD2.35M USD2.13M USD
Operating income−546.37M USD−31.91M USD−130.51M USD
Net income−528.26M USD−11.93M USD−108.14M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
83%
5 beats, 1 miss, 0 met estimates
Average EPS surprise
+328.24%
6 comparable reports
Latest EPS result
0.59
Estimate 0.62 · Miss by 4.07%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.720.490.260.03Q1 '25No estimateQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual 0.35, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 5, 2025: actual 0.212, estimate 0.086, surprise +147.03%, Beat. Q3 2025, reported Aug 5, 2025: actual 0.67, estimate 0.09, surprise +644.44%, Beat. Q4 2025, reported Nov 4, 2025: actual 0.34, estimate 0.24, surprise +41.67%, Beat. Q1 2026, reported Feb 10, 2026: actual 0.49, estimate 0.04, surprise +1125.00%, Beat. Q2 2026, reported May 5, 2026: actual 0.45, estimate 0.39, surprise +15.38%, Beat. Q3 2026, reported Aug 4, 2026: actual 0.59, estimate 0.615, surprise -4.07%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate 0.615, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates232.65M191.2M149.76M108.31MQ1 '25No estimateQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual 117.26M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 5, 2025: actual 123.83M USD, estimate 125.38M USD, surprise -1.24%, Miss. Q3 2025, reported Aug 5, 2025: actual 139.1M USD, estimate 125.38M USD, surprise +10.94%, Beat. Q4 2025, reported Nov 4, 2025: actual 154.21M USD, estimate 156.66M USD, surprise -1.56%, Miss. Q1 2026, reported Feb 10, 2026: actual 170.73M USD, estimate 156.66M USD, surprise +8.98%, Beat. Q2 2026, reported May 5, 2026: actual 182.31M USD, estimate 172.2M USD, surprise +5.87%, Beat. Q3 2026, reported Aug 4, 2026: actual 212.82M USD, estimate 201.46M USD, surprise +5.64%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 223.7M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$97.46

10.22% upside
Past 12 months12-month forecastHigh $125Average $97.46Low $65.00

Rating distribution

16 ratings
Strong buy00%
Buy1594%
Hold16%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions

HNGE news

investors.com

IPO Stock Of The Week: Hinge Health Finds Support At Key Level, Eyes New Buy Points

Hinge stock found support at a key level in recent weeks and is approaching multiple new buy points despite market weakness.

Read source
marketbeat.com

One Platform, Every Ailment: Hinge Health's Gamble

Many people know that seemingly unrelated symptoms can be connected. But in most cases, treating individual symptoms means a separate doctor visit, sometimes to different specialists, before the full picture emerges.

Read source
zacks.com

HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?

Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.

Read source
zacks.com

Reasons to Hold Hinge Health Stock in Your Portfolio for Now

HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.

Read source
zacks.com

Is Hinge Health Stock a Buy as Growth Accelerates and Risks Rise?

HNGE's rapid revenue growth, widening margins and higher 2026 outlook strengthen its case, but expansion raises execution risks.

Read source
zacks.com

Hinge Health's Cylinder Deal Opens a $135B GI Care Growth Opportunity

HNGE's $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.

Read source

HNGE peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding HNGE

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
110.76M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
91.65M
Weight
0.11%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
79.8M
Weight
0.04%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
50.68M
Weight
0.07%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
33.31M
Weight
0.22%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
27.24M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
17.51M
Weight
0.10%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
12.97M
Weight
0.06%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research HNGE

research.disclaimer